Frontiers in Neuroscience, Journal Year: 2024, Volume and Issue: 18
Published: Dec. 9, 2024
Alzheimer's disease (AD) is characterized by cerebral amyloid plaques and neurofibrillary tangles disruption of large-scale brain networks (LSBNs). Transcranial magnetic stimulation (TMS) has emerged as a potential non-invasive AD treatment that may serve an adjunct therapy with FDA approved medications.
Language: Английский
Biomedicines, Journal Year: 2024, Volume and Issue: 12(11), P. 2506 - 2506
Published: Nov. 1, 2024
Transcranial magnetic stimulation (TMS) methods have become exciting techniques for altering brain activity and improving synaptic plasticity, earning recognition as valuable non-medicine treatments a wide range of neurological disorders. Among these methods, repetitive TMS (rTMS) theta-burst (TBS) show significant promise in outcomes adults with complex neurodegenerative conditions, such Alzheimer's disease, stroke, Parkinson's etc. However, optimizing their effects remains challenge due to variability how patients respond limited understanding interact crucial neurotransmitter systems. This narrative review explores the mechanisms rTMS TBS, which enhance neuroplasticity functional improvement. We specifically focus on GABAergic glutamatergic pathways they key receptors like N-Methyl-D-Aspartate (NMDA) AMPA receptors, play essential roles processes long-term potentiation (LTP) depression (LTD). Additionally, we investigate TBS impact connectivity, particularly concerning brain-derived neurotrophic factor (BDNF) tropomyosin-related kinase receptor type B (TrkB). Here, highlight potential this research expand our better treatment patients. Through clarifying neurobiology behind neuroimaging findings, aim develop more effective, personalized plans that effectively address challenges posed by disorders ultimately quality neurorehabilitation services provide future directions patients' care.
Language: Английский
Citations
7
Journal of NeuroEngineering and Rehabilitation, Journal Year: 2025, Volume and Issue: 22(1)
Published: Feb. 5, 2025
Language: Английский
Citations
0
Journal of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown
Published: March 20, 2025
Background Alzheimer's disease (AD) is the most common neurodegenerative condition causing dementia. Currently, there has been no established non-pharmacological treatment for cognitive decline in patients with AD. Recent evidence suggests that repetitive transcranial magnetic stimulation (rTMS) may be effective as a non-invasive improving function Objective This study aimed to examine characteristics of rTMS protocols AD Methods We conducted systematic literature search on clinical trials AD, using PubMed, PsycINFO, and Scopus databases performed meta-analysis according PRISMA (Preferred Reporting Items Systematic Reviews Meta-Analyses) guidelines. To clarify which domains are improved by rTMS, meta-analyses were both global each domain including verbal memory, processing speed, executive function. In addition, sub-analyses details parameters sites, frequency, intensity, with/without neuro-navigation technique meta-regression analyses adjusting gender, education, number pulses performed. Results The results showed significant improvements function, while findings speed No found subgroup analysis or meta-regression. Conclusions enrich enhancement randomized controlled unified protocol larger sample size warranted.
Language: Английский
Citations
0
Journal of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: unknown
Published: March 23, 2025
Background Repetitive transcranial magnetic stimulation (rTMS) is an efficient intervention for alleviating cognitive symptoms in Alzheimer's disease (AD), but the optimal treatment duration high efficacy remains unclear. Objective This study investigates effects of 2-week and 4-week rTMS on neural network plasticity improvement, aiming to identify impairment. Methods was administered cognitively impaired patients over periods, exploring its improvement induced circuits. The also examines predictive value these circuits individual responses. Results significantly outperformed course improving function. Neural activity analysis identified precuneus as a key region episodic memory. Changes brain regions, particularly within default mode (DMN), visual (VN), motor (MN), were associated with improvements. Baseline functional connectivity regions predicted changes general cognition (r = 0.724, p < 0.001) memory 0.447, 0.022) after rTMS. Conclusions Extended enhances performance impairment patients, showing superior effects. Reduced DMN following linked baseline can predict patients’
Language: Английский
Citations
0
European journal of medical research, Journal Year: 2025, Volume and Issue: 30(1)
Published: April 4, 2025
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, affecting tens of millions worldwide with projections indicating increasing prevalence in coming decades. Characterized by progressive cognitive decline, AD manifests varying degrees executive, language, and visuospatial impairments that worsen over time, eventually leading to severe psychiatric symptoms, mobility difficulties, sleep disturbances, incontinence. While pharmacological treatments remain primary intervention approach, their efficacy often diminishes time may produce significant adverse effects. Repetitive transcranial magnetic stimulation (rTMS), as a non-invasive neuromodulation technique, has emerged promising alternative or complementary therapy. This literature review examines therapeutic potential mechanisms rTMS disease. Through electromagnetic induction, can selectively modulate cortical excitability, high-frequency (≥ 5 Hz) enhancing neural excitability low-frequency (≤ 1 producing inhibitory Recent clinical evidence demonstrates significantly improve function, memory, language abilities, motor performance patients, particularly when administered optimized parameters targeting key brain regions, such dorsolateral prefrontal cortex. The neurobiological underlying these effects include enhanced synaptic plasticity, increased expression neurotrophic factors, modulation neurotransmitter systems, reduction pathological protein aggregation. Meta-analyses indicate protocols (particularly 20 delivered at least 3 weeks minimum sessions improvements, potentially persisting for months post-treatment. Combined approaches integrating training show particular promise through synergistic enhancement neuroplasticity. Despite encouraging results, standardization treatment larger trials are needed establish definitive guidelines determine long-term efficacy. synthesizes current supporting an effective alleviating symptoms while highlighting opportunities advancing its application.
Language: Английский
Citations
0
Stress and Health, Journal Year: 2025, Volume and Issue: 41(2)
Published: April 1, 2025
ABSTRACT To systematically evaluate the intervention effect of repetitive transcranial magnetic stimulation (rTMS) combined with pharmacological interventions on sleep quality and depressive symptoms in patients depression, identify optimal parameters, explore potential clinical applications to facilitate individualised therapeutic strategies. Databases including Pubmed, Web Science, Cochrane Library, Embase, CNKI, Wanfang Medical Database, VIP database were searched up 31 December 2024, for randomized controlled trials (RCTs) assessing rTMS disorders depression. Data analysis was performed using Stata software. 17 RCTs involving 1667 included. Meta‐analysis revealed that significantly improved (SMD = −0.57, 95% CI: −1.02 −0.12, P < 0.05) reduced −0.73, −1.37 −0.10, 0.05). Subgroup analyses showed parameters improving high‐frequency targeting left dorsolateral prefrontal cortex, high intensity, low total pulse count (< 1200 pulses), session duration ≤ 20 min daily, 5–8 weeks. For symptoms, a daily treatment 21–30 more effective under similar parameter conditions. effectively improves alleviates showing dose‐dependent parameters. However, prolonged disease course or greater symptom severity, particularly those vascular other neurological comorbidities, alone may be insufficient. Integrating additional strategies tailoring personalised protocols necessary optimise outcomes. Future research should further synergistic orexin receptor antagonists (ORAs), offering novel, multimodal approach managing depression comorbid insomnia.
Language: Английский
Citations
0
Frontiers in Neuroscience, Journal Year: 2024, Volume and Issue: 18
Published: Dec. 9, 2024
Alzheimer's disease (AD) is characterized by cerebral amyloid plaques and neurofibrillary tangles disruption of large-scale brain networks (LSBNs). Transcranial magnetic stimulation (TMS) has emerged as a potential non-invasive AD treatment that may serve an adjunct therapy with FDA approved medications.
Language: Английский
Citations
0